Management of sunitinib-associated adverse events
Patients diagnosed with metastatic renal cell carcinoma (mRCC) are currently treated with oral tyrosine kinase inhibitors (TKIs). Sunitinib malate (Sutent R Pfizer INC) is an oral multitargeted TKI and is the mainstay of therapy for mRCC patients in Japan. Although it shows a high therapeutic respon...
Veröffentlicht in: | Hinyokika kiyo. Acta urologica Japonica. - 1962. - 58(2012), 11 vom: 28. Nov., Seite 639-46 |
---|---|
1. Verfasser: | |
Weitere Verfasser: | , , , |
Format: | Aufsatz |
Sprache: | Japanese |
Veröffentlicht: |
2012
|
Zugriff auf das übergeordnete Werk: | Hinyokika kiyo. Acta urologica Japonica |
Schlagworte: | Journal Article Antineoplastic Agents Indoles Pyrroles Sunitinib V99T50803M |